Stockscreener 앱 받기
0.0325
73.55%
-0.0847
전일 마감가:
$0.1172
열려 있는:
$0.04
하루 거래량:
108.07K
Relative Volume:
66.00
시가총액:
$N/A
수익:
$9.94M
순이익/손실:
$-144.49M
주가수익비율:
-0.00644
EPS:
-5.05
순현금흐름:
$-103.90M
1주 성능:
-73.55%
1개월 성능:
-79.82%
6개월 성능:
-98.42%
1년 성능:
-99.50%
1일 변동 폭
$0.0301
$0.04
1주일 범위
$0.0301
$0.04
52주 변동 폭
$0.0301
$0.04
Syros Pharmaceuticals Inc Stock (SYRS) Company Profile
SYRS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SYRS
Syros Pharmaceuticals Inc
|
0.0325 | 0 | 9.94M | -144.49M | -103.90M | -5.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.50 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Syros Pharmaceuticals Inc Stock (SYRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-11-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-09-22 | 개시 | Alliance Global Partners | Buy |
| 2020-01-17 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-03-08 | 재개 | JMP Securities | Mkt Outperform |
| 2019-02-14 | 재개 | Oppenheimer | Outperform |
| 2018-11-05 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2018-03-13 | 재확인 | Wedbush | Outperform |
| 2017-10-31 | 재개 | Piper Jaffray | Overweight |
| 2017-10-23 | 개시 | ROTH Capital | Neutral |
| 2017-08-10 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
모두보기
Syros Pharmaceuticals Inc 주식(SYRS)의 최신 뉴스
StockNews.com Begins Coverage on Syros Pharmaceuticals (NASDAQ:SYRS) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
StockNews.com Initiates Coverage on Syros Pharmaceuticals (NASDAQ:SYRS) - Defense World
Rege Nephro buys Tamibarotene-related assets from Syros Pharmaceuticals - MSN
Rege Nephro Acquires Assets from Syros Pharmaceuticals (SYRS) - GuruFocus
Rege Nephro Acquires Key Assets from Syros Pharmaceuticals (SYRS - GuruFocus
Rege Nephro Acquires Key Assets from Syros Pharmaceuticals (SYRS) | SYRS Stock News - GuruFocus
Major Kidney Disease Drug Acquisition: Rege Nephro Takes Over Syros' Phase 2 Asset - Stock Titan
Rege Nephro Acquires Tamibarotene-Related Assets from Syros Phar - GuruFocus
Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials - digitalmore.co
Syros Pharma pulls out of deal with RaQualia - The Pharma Letter
Syros Pharmaceuticals (NASDAQ:SYRS) Coverage Initiated at StockNews.com - Defense World
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Given Average Recommendation of “Hold” by Brokerages - Defense World
Syros Pharmaceuticals (NASDAQ:SYRS) Coverage Initiated by Analysts at StockNews.com - Defense World
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Short Interest Up 345.9% in March - Defense World
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Receives $3.33 Average PT from Brokerages - Defense World
Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by StockNews.com - Defense World
Syros Pharmaceuticals (SYRS) to Release Earnings on Wednesday - Defense World
Dow Dips Over 200 Points; US Industrial Production Increases More than Expected - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga India
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Analyze Syros Pharmaceuticals Inc (NASDAQ: SYRS) Before Investing. - stocksregister.com
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Finance Watch: Sutro Halves Workforce, Cuts Lead ADC And CEO Moves On - Citeline News & Insights
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Pre-market Movers: HCTI, HEPA, ZYXI, SYRS ... - RTTNews
US Stocks Mixed; Kohl's Shares Plunge After Q4 Results - Benzinga
Aptevo Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:APVO - Benzinga
Syros Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Syros Pharmaceuticals settles debt with Oxford Finance By Investing.com - Investing.com South Africa
Syros Pharmaceuticals settles debt with Oxford Finance - Investing.com India
Why US Stock Futures Are Rising TodayInvesco QQQ Trust, Series 1 (NASDAQ:QQQ), SPDR S&P 500 (ARCA:SPY) - Benzinga
Syros Pharmaceuticals, Inc. Announces Cessation of Gerald Quirk as Chief Executive Officer, Effective March 01, 2025 - Marketscreener.com
Syros Pharmaceuticals, Inc. Announces Management Changes -February 28, 2025 at 04:15 pm EST - Marketscreener.com
Stocks to Watch: Toro, Syros Pharmaceuticals - MarketWatch
Syros to delist from Nasdaq, deregister from SEC - MSN
Syros Pharmaceuticals Delists from Nasdaq Amid Restructuring - TipRanks
Syros Pharmaceuticals to Delist from Nasdaq, Deregister Common Shares -February 28, 2025 at 04:41 pm EST - Marketscreener.com
Syros Pharmaceuticals voluntarily delists from Nasdaq, deregisters common stock - TipRanks
Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration - Business Wire
Syros Pharmaceuticals stock hits 52-week low at $0.18 amid steep decline - MSN
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Syros Pharmaceuticals stock plunges to 52-week low of $0.16 - Investing.com
Syros Pharmaceuticals stock plunges to 52-week low of $0.16 By Investing.com - Investing.com South Africa
Syros Pharmaceuticals Inc (SYRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
0.52%
자본화:
|
볼륨(24시간):